SCYNEXIS AI Stock Analysis
SCYNEXIS (0L49) AI Stock Analysis
SCYNEXIS
(LSE:0L49)
No summary available
SCYNEXIS (0L49) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $20.19M
- Dividend Yield
- ―
- Average Volume (3M)
- 4,393
- Price to Earnings (P/E)
- -2.7
- Beta (1Y)
- 0.80
- Revenue Growth
- 543.96%
- EPS Growth
- 72.49%
- Country
- UK
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
SCYNEXIS Business Overview & Revenue Model
Company Description
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive can...
SCYNEXIS Risk Analysis
SCYNEXIS disclosed 44 risk factors in its most recent earnings report. SCYNEXIS reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksSCYNEXIS Peers Comparison
Overall Rating
AYTU62Neutral
CPIX53Neutral
RMTI52Neutral
TXMD50Neutral
IMCC39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 62Neutral | $19.35M | -1.30 | -52.89% | ― | -13.27% | 27.11% | |
| 53Neutral | $88.10M | 1.28 | 202.58% | 23.57% | -39.11% | -241.27% | |
| 52Neutral | $28.33M | -4.75 | -16.04% | ― | -3.96% | 7.97% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $21.64M | 230.86 | 0.45% | ― | 33.94% | -59.77% | |
| 39Underperform | $936.11K | -0.02 | 841.81% | ― | -35.33% | -127.87% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0L49 | SCYNEXIS Inc | 3.20 | -1.51 | -32.00% | |
| RMTI | Rockwell Medical | 7.03 | -1.63 | -18.78% | |
| TXMD | Therapeuticsmd Inc | 1.87 | 0.35 | 23.03% | |
| AYTU | Aytu BioScience | 1.78 | -0.20 | -10.10% | |
| CPIX | Cumberland Pharmaceuticals Inc. | 5.88 | 4.41 | 299.19% | |
| IMCC | Im Cannabis Corp | 0.57 | -29.39 | -98.10% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
